Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track

Cartesian Therapeutics, Inc.

Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.
Cash, equivalents and restricted cash $214.3M at Dec 31, 2024; expected to fund operations into mid-2027.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; FDA SPA agreement secured.
Preliminary Phase 2 SLE data expected 2H25; Phase 2 pediatric basket trial to initiate 2H25 in select autoimmune indications.
Dosing ongoing in first-in-human Phase 1 trial of Descartes-15 for multiple myeloma.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000059
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-03-13T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.659680+00:00
generated_at: 2026-05-24T20:54:48.690078+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000059
json_url: https://secwatch.observer/filing/0001453687-25-000059.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000059.md
text_url: https://secwatch.observer/filing/0001453687-25-000059.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/0001453687-25-000059-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/rnac-20250313.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-25-000059

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.